Seaport Therapeutics, Inc. is a clinical-stage therapeutics company, which engages in the provision of inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company was founded on April 1, 2024 and is headquartered in Boston, MA.
相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
Enrolling By Invitation
1
50.0%
招募中
1
50.0%
暂无批准数据
- After more than a decade without major breakthroughs in anxiety medication, three promising treatments using novel mechanisms are advancing through clinical trials toward potential 2026 FDA consideration. - MindMed's MM120, a psychedelic-derived treatment using controlled LSD doses, has entered Phase 3 trials for generalized anxiety disorder after showing 12-week benefits from a single dose in Phase 2 studies. - Seaport Therapeutics' GlyphAllo offers an oral formulation of allopregnanolone for depression with anxious distress, while Vistagen's Fasedienol nasal spray targets social anxiety through direct nasal-to-brain delivery. - These investigational treatments represent a shift toward new biological targets and precision delivery systems beyond traditional SSRIs and benzodiazepines, potentially offering faster-acting and more personalized therapeutic options.
- Monash University has established the Monash Boston Hub in Cambridge to deepen collaborations with North American and European biotech companies for drug discovery and health innovations. - The university has completed over 160 license deals and created 30+ spinout companies in the past five years, collectively raising nearly $1 billion in investment. - The Hub will be staffed by 5-7 development professionals and aims to accelerate licensing deals, clinical trial collaborations, and partnerships with global biotech innovators. - Monash has existing partnerships with major companies including Moderna, CRISPR Therapeutics, and Seaport Therapeutics, demonstrating its proven track record in translating research into commercial applications.
- Seaport Therapeutics has dosed the first patient in its phase 2b BUOY-1 trial of GlyphAllo, a novel oral prodrug of allopregnanolone for major depressive disorder with or without anxious distress. - The global study will enroll up to 360 participants randomized to receive GlyphAllo or placebo once daily over six weeks, with the primary endpoint being change in HAM-D-17 depression scores. - Phase 1 data showed GlyphAllo achieved nine times greater allopregnanolone exposure than oral dosing and matched efficacious IV levels, while phase 2a results demonstrated significant stress hormone reduction. - If successful, GlyphAllo could become a first-in-class treatment for the approximately 280 million people globally affected by major depression, with nearly 60% also experiencing anxious distress.
• Seaport Therapeutics has raised $225 million in Series B funding, led by General Atlantic, to develop innovative oral treatments for depression and anxiety using their proprietary Glyph technology. • The company's lead candidate SPT-300, an oral prodrug of allopregnanolone for major depressive disorder, has advanced to Phase 2b trials with potential for regulatory submission. • Seaport's pipeline includes SPT-320 for generalized anxiety disorder and SPT-348, representing the first potential new anxiety treatment mechanism in decades.
• Seaport Therapeutics' SPT-300, an allopregnanolone prodrug, demonstrates good tolerability in a Phase I trial with 99 healthy volunteers, highlighting its safety profile. • The study observed therapeutically relevant blood levels of SPT-300, up to nine times greater than orally administered unmodified allopregnanolone, suggesting enhanced bioavailability. • EEG data showed increases in beta frequency power and a reduction in saccadic eye velocity, indicating rapid pharmacodynamic activity of SPT-300 on the central nervous system. • SPT-300 is being developed for neurological and neuropsychiatric conditions, including major depressive disorder, with a Phase IIb trial planned to further assess its efficacy.
• Seaport Therapeutics closed an oversubscribed $225 million Series B financing round to advance its clinical-stage pipeline of neuropsychiatric medicines. • The funding will support the clinical development of SPT-300 for major depressive disorder and SPT-320 for generalized anxiety disorder. • Seaport's Glyph platform enhances oral bioavailability and reduces side effects of drugs by utilizing the lymphatic system for drug absorption. • The Glyph platform has the potential to revive clinically effective drugs previously limited by poor drug properties or tolerability issues.
